Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: A first step toward implementing a multidisciplinary, evidence-based guideline

Hermens, Rosella; Ouwens, Mariëlle; Vonk-Okhuijsen, Saskia; Wel, Y. van der; Tjan‐Heijnen, Vivianne C. G.; Broek, L.D. van den; Ho, Vincent K.Y.; Janssen‐Heijnen, M.L.G.; Groen, Harry J.M.; Grol, Richard; Wollersheim, H.C.H.

doi:10.1016/j.lungcan.2006.07.001

Cited by 108 publications

(108 citation statements)

References 23 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…For Denmark, the Netherlands and Germany, the process of the development of national quality indicator sets for lung cancer care, as well as their evaluation, were described providing valuable information on the reference intervals of these tools [65][66][67]. Two recent review articles by LENNES et al [68] and TANVETYANON [69] describe quality indicator systems for lung cancer care.…”

Section: Resultsmentioning

confidence: 99%

The European initiative for quality management in lung cancer care

Blum¹,

Rich²,

Baldwin³

et al. 2014

European Respiratory Journal

View full text Add to dashboard Cite

Lung cancer is the commonest cause of cancer-related death worldwide and poses a significant respiratory disease burden. Little is known about the provision of lung cancer care across Europe. The overall aim of the Task Force was to investigate current practice in lung cancer care across Europe.The Task Force undertook four projects: 1) a narrative literature search on quality management of lung cancer; 2) a survey of national and local infrastructure for lung cancer care in Europe; 3) a benchmarking project on the quality of (inter)national lung cancer guidelines in Europe; and 4) a feasibility study of prospective data collection in a pan-European setting.There is little peer-reviewed literature on quality management in lung cancer care. The survey revealed important differences in the infrastructure of lung cancer care in Europe. The European guidelines that were assessed displayed wide variation in content and scope, as well as methodological quality but at the same time there was relevant duplication. The feasibility study demonstrated that it is, in principle, feasible to collect prospective demographic and clinical data on patients with lung cancer. Legal obligations vary among countries.The European Initiative for Quality Management in Lung Cancer Care has provided the first comprehensive snapshot of lung cancer care in Europe. Executive summaryThis European Respiratory Society (ERS) Task Force report describes the first phase of an ambitious initiative with the ultimate aim to improve the quality of care for people with lung cancer across Europe. The Task Force undertook four projects. 1) An extensive review of the literature on quality management revealed evidence that was mainly limited to individual aspects of quality improvement. 2) A baseline survey of national and local infrastructure of healthcare showed marked differences in resources and access to care among 37 countries. 3) A benchmarking project on the quality of guidelines showed that well-resourced guidelines were better. 4) A feasibility study showed that contemporary clinical data collection was possible through a clinical network representing 28 European countries. The Task Force has created a platform for future research and development of initiatives that may lead to improved care for people with lung cancer in Europe.

show abstract

Section: Resultsmentioning

confidence: 99%

The European initiative for quality management in lung cancer care

Blum¹,

Rich²,

Baldwin³

et al. 2014

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…5 This set of indicators was based on national and international evidencebased guidelines for the diagnosis and treatment of patients with NSCLC, and includes the opinions of patients and professionals, and consists of 14 indicators: 4 regarding professional evidence-based quality, 3 regarding organizational quality, and 7 regarding patient-oriented quality ( Table 1).…”

Section: Quality Indicators and Data Collectionmentioning

confidence: 99%

“…Recently, we developed a set of quality indicators for patients with NSCLC based on evidence-based guidelines and the opinions of professionals and patients. 5 Determinants of either high or low quality of care for patients with NSCLC can be related to patient, professional, or hospital characteristics, such as patient age, 6 health status, 7 stage of disease, comorbidity, 8 years of experience of the professionals involved, 9 their knowledge of guidelines and barriers to the implementation of guidelines, 10,11 the size of the hospital and the patient volume treated, 12,13 teaching activities in the hospital, 14 and the availability and functioning of a multidisciplinary lung cancer team or specialized nurses with coordination tasks. 2,15 Insight into determinants that influence the quality of care can help to design targeted strategies with which to improve care.…”

mentioning

confidence: 99%

Quality of integrated care for patients with nonsmall cell lung cancer

Ouwens

Hermens

Termeer

et al. 2007

Cancer

View full text Add to dashboard Cite

Mammalian cells play a dominant role in the industrial production of biopharmaceutical proteins. However, the productivity of producer cells is often hindered by a bottleneck in the saturated secretory pathway, where a sophisticated mechanism of vesicle trafficking is mediated by numerous proteins and their complexes, among which are the cross‐kingdom conserved SNAREs [soluble NSF (N‐ethylmaleimide‐sensitive factor) receptor]. The SNAREs assemble into complexes by means of four interactive α‐helices and, thus, trigger the fusion of transport vesicles with the respective target membranes. We report that the transgenic expression of exocytic SNAREs, which control the fusion of secretory vesicles to the plasma membrane, differentially impacts the secretory capacity of HEK‐293, HeLa, and CHO‐K1 cells. While other exocytic SNAREs have no effect or a negative effect, SNAP‐23 [synaptosome‐associated protein of 23 kDa] and VAMP8 [vesicle‐associated membrane protein 8] specifically increase the production of recombinant proteins when they are ectopically and stably expressed in mammalian cells. The targeted and effective intervention in the secretory capacity of SNARE proteins is a novel engineering strategy, which could lead to the development of new therapies by increasing the production of biopharmaceutical proteins or by boosting the secretion of cell implants in cell therapy initiatives. Biotechnol. Bioeng. 2011; 108:611–620. © 2010 Wiley Periodicals, Inc.

show abstract

“…3 Many diseases have measures that can be used to address the quality of care. Diseases such as stroke, 4 Parkinson's, 5 asthma, 6 nonsmall cell lung cancer, 7 or breast cancer 8 can be assessed by quality of care indicators. Indicators can also be used to assess other health status components and care procedures, such as cardiovascular care, 9 injury outcome, 10 opioid treatment programs, 11 and cancer care at the end of life.…”

Section: Introductionmentioning

confidence: 99%